-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FPA-150 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPA-150 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPA-150 in Triple-Negative Breast Cancer (TNBC) Drug Details: FPA-150 is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – FPA-150 in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - FPA-150 in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. FPA-150 in Metastatic Breast Cancer Drug Details: FPA-150 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – FPA-150 in Epithelial Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.FPA-150 in Epithelial Ovarian CancerDrug Details:FPA-150 is under development for the treatment of advanced or metastatic...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Elebsiran in Hepatitis B
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Elebsiran in Hepatitis B report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Elebsiran in Hepatitis BDrug Details: Elebsiran (VIR-2218) is under development for the treatment...
-
Company Profile
Five Prime Therapeutics Inc – Company Profile
Five Prime Therapeutics Inc (Five Prime), a subsidiary of Amgen Inc, is a clinical state biopharmaceutical company focusing on the research and development of novel treatments for cancer and inflammatory disorders. The company’s developmental pipeline is based on the discovery platform and library of therapeutic proteins. The company’s pipeline products include cabiralizumab; Bemarituzumab (FPA144); FPT155; FPA157; and BMS-986258. Five Prime has also developed proprietary protein screening technologies and rapid in vivo protein production system to identify new targets for protein...
Add to Basket -
Sector Analysis
Contract Injectable Packaging Trends in the Bio/Pharma Industry
Injectables and their packaging requirements are very important to marketed treatments given the volume of vaccines required to tackle the COVID-19 pandemic and the rising number of biologics in development pipelines and on the market. Most injectable drugs in the development pipeline are biologics, which will become increasingly approved and more established in the treatment landscape in the future. The top contract packaging organizations (CPOs) for injectables by the number of contracts are standalone packagers along with large CMOs which...
-
Sector Analysis
United States In Vitro Diagnostics Market Outlook to 2025 – Cardiac Disease, Clinical Chemistry, Hematological Disorders and Others
GlobalData’s “United States In Vitro Diagnostics Market Outlook to 2025” is a comprehensive databook report, covering key market data on the United States In Vitro Diagnostics market. The databook report provides value (USD), volume (units) and average prices (USD) within market segments – Cardiac Disease, Clinical Chemistry, Hematological Disorders, Hormonal Disorders, Infectious Disease, IVD Analyzers and Reagents, Metabolic Disorder, Oncology and Women's Health. The United States In Vitro Diagnostics Market report provides key information and data on: • Annualized market...
-
Product Insights
Ovarian Cancer Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Ovarian Cancer Global Clinical Trials Review, H1, 2018" provides an overview of Ovarian Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Ovarian Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Gastric Cancer Global Clinical Trials Review, H2, 2017
GlobalData's clinical trial report, “Gastric Cancer Global Clinical Trials Review, H2, 2017" provides an overview of Gastric Cancer clinical trials scenario. This report provides top line data relating to the clinical trials on Gastric Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...